CN104450747A - 用于治疗Leber遗传性视神经病变的重组腺相关病毒-NADH脱氢酶亚单位4基因全长以及药剂 - Google Patents
用于治疗Leber遗传性视神经病变的重组腺相关病毒-NADH脱氢酶亚单位4基因全长以及药剂 Download PDFInfo
- Publication number
- CN104450747A CN104450747A CN201410491726.XA CN201410491726A CN104450747A CN 104450747 A CN104450747 A CN 104450747A CN 201410491726 A CN201410491726 A CN 201410491726A CN 104450747 A CN104450747 A CN 104450747A
- Authority
- CN
- China
- Prior art keywords
- medicament
- gene
- cag
- aav2
- nadh dehydrogenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 title claims abstract description 22
- 101710088194 Dehydrogenase Proteins 0.000 title abstract description 5
- 101150033839 4 gene Proteins 0.000 title abstract 2
- 108010063499 Sigma Factor Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 239000002773 nucleotide Substances 0.000 claims abstract description 7
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 7
- 108010035095 NADH dehydrogenase subunit 4 Proteins 0.000 claims description 65
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 claims description 64
- 239000000463 material Substances 0.000 claims description 8
- 210000004907 gland Anatomy 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 241001300078 Vitrea Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- -1 α, α-trehalose dihydrate compound Chemical class 0.000 claims description 4
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 3
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229960003882 histidine monohydrochloride monohydrate Drugs 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 102000057593 human F8 Human genes 0.000 claims 1
- 229940047431 recombinate Drugs 0.000 claims 1
- 238000001890 transfection Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 7
- 210000001328 optic nerve Anatomy 0.000 abstract description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract description 2
- 210000003470 mitochondria Anatomy 0.000 abstract 2
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000025608 mitochondrion localization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 18
- 101001109052 Homo sapiens NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 description 11
- 210000001525 retina Anatomy 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000702421 Dependoparvovirus Species 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000012888 bovine serum Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 101150115542 Cox10 gene Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 101100440806 Cereibacter sphaeroides (strain ATCC 17023 / DSM 158 / JCM 6121 / CCUG 31486 / LMG 2827 / NBRC 12203 / NCIMB 8253 / ATH 2.4.1.) ctaB gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 101100114478 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pft-1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010008795 Chromatopsia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150100316 ND4 gene Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 101150024923 da gene Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410491726.XA CN104450747B (zh) | 2014-09-23 | 2014-09-23 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410491726.XA CN104450747B (zh) | 2014-09-23 | 2014-09-23 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104450747A true CN104450747A (zh) | 2015-03-25 |
CN104450747B CN104450747B (zh) | 2018-02-09 |
Family
ID=52897498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410491726.XA Active CN104450747B (zh) | 2014-09-23 | 2014-09-23 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104450747B (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109207520A (zh) * | 2018-09-25 | 2019-01-15 | 北京五加和分子医学研究所有限公司 | Leber遗传性视神经病变的基因药物 |
CN109970861A (zh) * | 2017-12-27 | 2019-07-05 | 武汉纽福斯生物科技有限公司 | 一种靶向线粒体的nd4融合蛋白及其制备方法和应用 |
WO2019241206A1 (en) * | 2018-06-11 | 2019-12-19 | Gensight Biologics Sa | Recombinant aav vectors and methods of using the same |
JP2019537578A (ja) * | 2016-11-04 | 2019-12-26 | バクスアルタ インコーポレイテッド | アデノ随伴ウイルス製剤 |
WO2020000641A1 (zh) * | 2018-06-29 | 2020-01-02 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位蛋白的核酸及其应用 |
CN110656117A (zh) * | 2018-06-29 | 2020-01-07 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位6蛋白的核酸及其应用 |
WO2020010491A1 (zh) * | 2018-07-09 | 2020-01-16 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN110699367A (zh) * | 2018-07-09 | 2020-01-17 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN110724695A (zh) * | 2018-06-29 | 2020-01-24 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
WO2020037938A1 (zh) * | 2018-08-20 | 2020-02-27 | 武汉纽福斯生物科技有限公司 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
CN110857440A (zh) * | 2018-08-23 | 2020-03-03 | 武汉纽福斯生物科技有限公司 | 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 |
CN110964748A (zh) * | 2018-09-29 | 2020-04-07 | 武汉纽福斯生物科技有限公司 | 含线粒体靶向序列的载体及其构建方法和应用 |
WO2020077756A1 (zh) * | 2018-10-19 | 2020-04-23 | 武汉纽福斯生物科技有限公司 | Nd4蛋白的编码序列及其应用 |
CN111068071A (zh) * | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
KR20210027374A (ko) * | 2018-06-29 | 2021-03-10 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
CN112584874A (zh) * | 2018-08-20 | 2021-03-30 | 武汉纽福斯生物科技有限公司 | 用于治疗莱伯氏遗传性视神经病变的组合物和方法 |
WO2021115317A1 (en) * | 2019-12-09 | 2021-06-17 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy with nadh dehydrogenase proteins |
CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102634527A (zh) * | 2012-04-11 | 2012-08-15 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
WO2013138244A2 (en) * | 2012-03-12 | 2013-09-19 | Medimmune, Llc | Treatment of multiple sclerosis with anti-cd19 antibody |
-
2014
- 2014-09-23 CN CN201410491726.XA patent/CN104450747B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013138244A2 (en) * | 2012-03-12 | 2013-09-19 | Medimmune, Llc | Treatment of multiple sclerosis with anti-cd19 antibody |
CN102634527A (zh) * | 2012-04-11 | 2012-08-15 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
Non-Patent Citations (3)
Title |
---|
HAN PEI,ET AL: "Construction and Detection of a Novel Type of Recombinant Human rAAV2/2-ND4", 《CONSTRUCTION AND DETECTION OF A NOVEL TYPE OF RECOMBINANT HUMAN RAAV2/2-ND4》 * |
PATERSON,R.G,ET AL: "GU299216.1", 《GENBANK》 * |
RAJESHWARI D. KOILKONDA,ET AL: "Safety and Effects of the Vector for the Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial", 《JAMA OPHTHALMOL》 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019537578A (ja) * | 2016-11-04 | 2019-12-26 | バクスアルタ インコーポレイテッド | アデノ随伴ウイルス製剤 |
CN109970861A (zh) * | 2017-12-27 | 2019-07-05 | 武汉纽福斯生物科技有限公司 | 一种靶向线粒体的nd4融合蛋白及其制备方法和应用 |
CN109970861B (zh) * | 2017-12-27 | 2021-06-11 | 武汉纽福斯生物科技有限公司 | 一种靶向线粒体的nd4融合蛋白及其制备方法和应用 |
CN112384625A (zh) * | 2018-06-11 | 2021-02-19 | 珍视生物股份公司 | 重组aav载体及其使用方法 |
WO2019241206A1 (en) * | 2018-06-11 | 2019-12-19 | Gensight Biologics Sa | Recombinant aav vectors and methods of using the same |
CN110724695A (zh) * | 2018-06-29 | 2020-01-24 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
KR20210027374A (ko) * | 2018-06-29 | 2021-03-10 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
KR102627561B1 (ko) * | 2018-06-29 | 2024-01-24 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
US11332741B1 (en) | 2018-06-29 | 2022-05-17 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
JP2021529001A (ja) * | 2018-06-29 | 2021-10-28 | ウーハン ニューロフス バイオテクノロジー リミテッド カンパニーWuhan Neurophth Biotechnology Limited Company | レーベル遺伝性視神経症を治療するための組成物及び方法 |
CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
US11034954B2 (en) | 2018-06-29 | 2021-06-15 | Wuhan Neurophth Biological Technology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
WO2020000641A1 (zh) * | 2018-06-29 | 2020-01-02 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位蛋白的核酸及其应用 |
CN110656117A (zh) * | 2018-06-29 | 2020-01-07 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位6蛋白的核酸及其应用 |
CN110699367A (zh) * | 2018-07-09 | 2020-01-17 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN110699367B (zh) * | 2018-07-09 | 2021-06-11 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
WO2020010491A1 (zh) * | 2018-07-09 | 2020-01-16 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN112584874A (zh) * | 2018-08-20 | 2021-03-30 | 武汉纽福斯生物科技有限公司 | 用于治疗莱伯氏遗传性视神经病变的组合物和方法 |
CN110846392A (zh) * | 2018-08-20 | 2020-02-28 | 武汉纽福斯生物科技有限公司 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
US11352645B2 (en) | 2018-08-20 | 2022-06-07 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating Leber's hereditary optic neuropathy |
WO2020037938A1 (zh) * | 2018-08-20 | 2020-02-27 | 武汉纽福斯生物科技有限公司 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
CN110857440A (zh) * | 2018-08-23 | 2020-03-03 | 武汉纽福斯生物科技有限公司 | 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 |
CN109207520B (zh) * | 2018-09-25 | 2022-05-10 | 北京锦篮基因科技有限公司 | Leber遗传性视神经病变的基因药物 |
CN109207520A (zh) * | 2018-09-25 | 2019-01-15 | 北京五加和分子医学研究所有限公司 | Leber遗传性视神经病变的基因药物 |
CN110964748A (zh) * | 2018-09-29 | 2020-04-07 | 武汉纽福斯生物科技有限公司 | 含线粒体靶向序列的载体及其构建方法和应用 |
CN110964748B (zh) * | 2018-09-29 | 2022-09-02 | 武汉纽福斯生物科技有限公司 | 含线粒体靶向序列的载体及其构建方法和应用 |
WO2020077756A1 (zh) * | 2018-10-19 | 2020-04-23 | 武汉纽福斯生物科技有限公司 | Nd4蛋白的编码序列及其应用 |
WO2020082417A1 (zh) * | 2018-10-22 | 2020-04-30 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传性视神经病变 |
CN111068071A (zh) * | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
WO2021115317A1 (en) * | 2019-12-09 | 2021-06-17 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy with nadh dehydrogenase proteins |
CN113025633A (zh) * | 2019-12-09 | 2021-06-25 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
US11357869B2 (en) | 2019-12-09 | 2022-06-14 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy with NADH dehydrogenase proteins |
CN114929872A (zh) * | 2019-12-09 | 2022-08-19 | 武汉纽福斯生物科技有限公司 | 用nadh脱氢酶蛋白治疗莱伯遗传性视神经病变的组合物和方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104450747B (zh) | 2018-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104450747B (zh) | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 | |
CN102634527B (zh) | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 | |
JP2022062026A (ja) | 二重グリカン結合性aavベクターのための方法および組成物 | |
US20140294893A1 (en) | Recombinant nonpathogenic mdv vector providing multivalent immunity | |
CN104721817B (zh) | 一种疫苗组合物及其制备方法和应用 | |
JP2022529662A (ja) | 二重グリカン結合aav2.5ベクターのための方法および組成物 | |
CN108570457A (zh) | 一种增强猪瘟脾淋弱毒疫苗效价的体外培养方法 | |
CN105838684A (zh) | 一种猪CD40L/GMCSF/PCV2Cap重组腺病毒的构建、扩增及纯化方法 | |
CN108421037A (zh) | 一种猪伪狂犬病/猪细小病毒病二联灭活疫苗及其悬浮培养制备方法 | |
CN117247973B (zh) | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途 | |
CN103060356A (zh) | 鸭瘟病毒缺失gE基因转移载体及其构建方法 | |
CN102973952A (zh) | 表达传染性法氏囊病病毒多聚蛋白基因vp243的dna疫苗及其构建方法和应用 | |
CN108635574A (zh) | 一种生产鸭坦布苏、禽流感二联灭活疫苗的方法及其产品 | |
CN108704128A (zh) | 一种犬瘟热细小病毒二联亚单位疫苗 | |
CN107334777A (zh) | 干扰btf3在抑制黑色素瘤细胞增殖中的新用途 | |
Cao et al. | A rAAV2/6 Mutant with enhanced targeting for mouse retinal müller cells | |
CN114432332A (zh) | circUTRN在制备治疗心力衰竭药物中的应用、重组载体和治疗心力衰竭的药物 | |
CN101444629B (zh) | 一种非注射用的基因治疗药物及其药盒 | |
CN107137705B (zh) | 猪伪狂犬gE基因缺失病毒灭活疫苗的生产方法 | |
CN117511946A (zh) | 特异性靶向scgII基因的sgRNA及其应用 | |
CN116284350B (zh) | 一种猫疱疹病毒单克隆抗体及其制备方法和应用 | |
CN116254237B (zh) | 一种降低眼压的表达nrp1的重组腺相关病毒的构建方法及其应用 | |
CN114517209B (zh) | 环状RNA circTTC3过表达腺相关病毒载体、腺相关病毒及其应用 | |
CN116751818B (zh) | 一种重组流感病毒载体治疗性高血压疫苗的制备方法 | |
CN110946866B (zh) | 达匹维林在制备抑制鱼类病毒性出血性败血症病毒对细胞感染的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180112 Address after: 430000, Hubei, East Lake Province, Wuhan hi tech Development Zone, 666 hi tech Avenue, Wuhan National Bio Industry Base Project B, C and D District R & D building B1, C270-C271 Applicant after: Wuhan Niufusi Biological Technology Co. Ltd. Address before: 430030 Department of Ophthalmology, Tongji Hospital, 1095 Jiefang Avenue, Hubei, Wuhan Applicant before: Li Bin |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150325 Assignee: Newforce (Suzhou) Biotechnology Co.,Ltd. Assignor: Wuhan Niufusi Biological Technology Co.,Ltd. Contract record no.: X2021420000011 Denomination of invention: Recombinant adeno-associated virus NADH dehydrogenase subunit 4 gene for the treatment of Leber hereditary optic neuropathy Granted publication date: 20180209 License type: Common License Record date: 20210322 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Newforce (Suzhou) Biotechnology Co.,Ltd. Assignor: Wuhan Niufusi Biological Technology Co.,Ltd. Contract record no.: X2021420000011 Date of cancellation: 20210709 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150325 Assignee: Newforce (Suzhou) Biotechnology Co.,Ltd. Assignor: Wuhan Niufusi Biological Technology Co.,Ltd. Contract record no.: X2021420000020 Denomination of invention: Full length of recombinant adeno-associated virus NADH dehydrogenase subunit 4 gene and agent for the treatment of Leber hereditary optic neuropathy Granted publication date: 20180209 License type: Common License Record date: 20210726 |
|
EE01 | Entry into force of recordation of patent licensing contract |